Uncategorized
CNV reduced with ICON-1 treatment in phase 2 trial
BOSTON — Choroidal neovascularization was reduced at 6 months in patients with age-related macular degeneration who were treated with ICON-1, according to a study presented here at the American Society of Retina Specialists meeting. Christine R. Gonzales, MD, reported the results of the phase 2 EMERGE study of ICON-1 (Iconic Therapeutics), an anti-tissue factor immunoconjugate protein, being studied to determine its biological effect on choroidal neovascularization.